Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Nov;39(11):2535–2540. doi: 10.1128/aac.39.11.2535

Prevention of experimental endotoxin shock by a monocyte activator.

B Passlick 1, M O Labeta 1, J R Izbicki 1, P Ostertag 1, T Löffler 1, M Siebeck 1, U Pichlmeier 1, L Schweiberer 1, H W Ziegler-Heitbrock 1
PMCID: PMC162979  PMID: 8585740

Abstract

In patients with polytrauma or major surgery, severe bacterial infections leading to septic shock and multiorgan failure are still a major cause of death. Prevention of septic shock in patients at risk would be an alternative to treatment of patients with overt septic shock. We therefore conducted a trial with the monocyte activator muramyl tripeptide phosphatidylethanolamine (MTP-PE) in an experimental pig model. Liposome encapsulated MTP-PE (50 micrograms/kg of body weight) or liposomes alone were given intravenously at 72 or 24 h before endotoxemia was induced by lipopolysaccharide (LPS), simultaneously with the induction of endotoxin shock, or 1 h thereafter. Pretreatment with MTP-PE at 72 and 24 h before endotoxemia was induced resulted in a reduction of endotoxin shock-induced mortality from 81.8% (9 of 11 animals) in the control group to 8.3% (1 of 12 animals) of the MTP-PE-pretreated animals (P < 0.001). The administration of MTP-PE 24 h before the induction of endotoxin shock was more effective (P < 0.01) than administration of MTP-PE 72 h before endotoxemia was induced (P = 0.05). The pretreated animals did not develop fever or cardiovascular complications, and pulmonary function was significantly improved. Furthermore, the alpha-form of the soluble CD14 LPS receptor in pig serum showed a marked decrease in LPS-treated animals, and this decrease was reduced by MTP-PE pretreatment at 24 h before endotoxemia was induced. When MTP-PE was given simultaneously with the induction of septic shock or 1 h thereafter, it did not influence either mortality or morbidity. In conclusion, pretreatment of pigs with MTP-PE improves several parameters of endotoxin shock and it reduces mortality. Patients with high risk of developing septic complications might benefit from a pretreatment with this monocyte-activating substance.

Full Text

The Full Text of this article is available as a PDF (299.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arditi M., Zhou J., Dorio R., Rong G. W., Goyert S. M., Kim K. S. Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14. Infect Immun. 1993 Aug;61(8):3149–3156. doi: 10.1128/iai.61.8.3149-3156.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  3. Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A. 1977 May;74(5):2089–2093. doi: 10.1073/pnas.74.5.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dietrich F. M., Hochkeppel H. K., Lukas B. Enhancement of host resistance against virus infections by MTP-PE, a synthetic lipophilic muramyl peptide--I. Increased survival in mice and guinea pigs after single drug administration prior to infection, and the effect of MTP-PE on interferon levels in sera and lungs. Int J Immunopharmacol. 1986;8(8):931–942. doi: 10.1016/0192-0561(86)90095-0. [DOI] [PubMed] [Google Scholar]
  5. Dunn D. L. Role of endotoxin and host cytokines in septic shock. Chest. 1991 Sep;100(3 Suppl):164S–168S. doi: 10.1378/chest.100.3_supplement.164s. [DOI] [PubMed] [Google Scholar]
  6. Durieux J. J., Vita N., Popescu O., Guette F., Calzada-Wack J., Munker R., Schmidt R. E., Lupker J., Ferrara P., Ziegler-Heitbrock H. W. The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol. 1994 Sep;24(9):2006–2012. doi: 10.1002/eji.1830240911. [DOI] [PubMed] [Google Scholar]
  7. Faradji A., Bohbot A., Frost H., Schmitt-Goguel M., Siffert J. C., Dufour P., Eber M., Lallot C., Wiesel M. L., Bergerat J. P. Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis. J Clin Oncol. 1991 Jul;9(7):1251–1260. doi: 10.1200/JCO.1991.9.7.1251. [DOI] [PubMed] [Google Scholar]
  8. Fearns C., Kravchenko V. V., Ulevitch R. J., Loskutoff D. J. Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide. J Exp Med. 1995 Mar 1;181(3):857–866. doi: 10.1084/jem.181.3.857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Frey E. A., Miller D. S., Jahr T. G., Sundan A., Bazil V., Espevik T., Finlay B. B., Wright S. D. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1992 Dec 1;176(6):1665–1671. doi: 10.1084/jem.176.6.1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Frost H., Murray J. L., Chaudri H. A., Van Damme J. Interleukin-6 induction by a muramyltripeptide derivative in cancer patients. J Biol Response Mod. 1990 Apr;9(2):160–166. [PubMed] [Google Scholar]
  11. Haas J. G., Baeuerle P. A., Riethmüller G., Ziegler-Heitbrock H. W. Molecular mechanisms in down-regulation of tumor necrosis factor expression. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9563–9567. doi: 10.1073/pnas.87.24.9563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Izbicki J. R., Raedler C., Anke A., Brunner P., Siebeck M., Leinisch E., Lüttiken R., Ruckdeschel G., Wilker D. K., Schweiberer L. Beneficial effect of liposome-encapsulated muramyl tripeptide in experimental septicemia in a porcine model. Infect Immun. 1991 Jan;59(1):126–130. doi: 10.1128/iai.59.1.126-130.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kleinerman E. S., Jia S. F., Griffin J., Seibel N. L., Benjamin R. S., Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992 Aug;10(8):1310–1316. doi: 10.1200/JCO.1992.10.8.1310. [DOI] [PubMed] [Google Scholar]
  14. Kleinerman E. S., Murray J. L., Snyder J. S., Cunningham J. E., Fidler I. J. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res. 1989 Aug 15;49(16):4665–4670. [PubMed] [Google Scholar]
  15. Krüger C., Schütt C., Obertacke U., Joka T., Müller F. E., Knöller J., Köller M., König W., Schönfeld W. Serum CD14 levels in polytraumatized and severely burned patients. Clin Exp Immunol. 1991 Aug;85(2):297–301. doi: 10.1111/j.1365-2249.1991.tb05722.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Labeta M. O., Durieux J. J., Fernandez N., Herrmann R., Ferrara P. Release from a human monocyte-like cell line of two different soluble forms of the lipopolysaccharide receptor, CD14. Eur J Immunol. 1993 Sep;23(9):2144–2151. doi: 10.1002/eji.1830230915. [DOI] [PubMed] [Google Scholar]
  17. Langhans W., Savoldelli D., Weingarten S. Comparison of the feeding responses to bacterial lipopolysaccharide and interleukin-1 beta. Physiol Behav. 1993 Apr;53(4):643–649. doi: 10.1016/0031-9384(93)90168-f. [DOI] [PubMed] [Google Scholar]
  18. Lazdins J. K., Woods-Cook K., Walker M., Alteri E. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Res Hum Retroviruses. 1990 Oct;6(10):1157–1161. doi: 10.1089/aid.1990.6.1157. [DOI] [PubMed] [Google Scholar]
  19. MacEwen E. G., Kurzman I. D., Rosenthal R. C., Smith B. W., Manley P. A., Roush J. K., Howard P. E. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989 Jun 21;81(12):935–938. doi: 10.1093/jnci/81.12.935. [DOI] [PubMed] [Google Scholar]
  20. Mathison J. C., Virca G. D., Wolfson E., Tobias P. S., Glaser K., Ulevitch R. J. Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages. J Clin Invest. 1990 Apr;85(4):1108–1118. doi: 10.1172/JCI114542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Melissen P. M., van Vianen W., Rijsbergen Y., Bakker-Woudenberg I. A. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimental Klebsiella pneumoniae infection. Infect Immun. 1992 Jan;60(1):95–101. doi: 10.1128/iai.60.1.95-101.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Murray J. L., Kleinerman E. S., Cunningham J. E., Tatom J. R., Andrejcio K., Lepe-Zuniga J., Lamki L. M., Rosenblum M. G., Frost H., Gutterman J. U. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol. 1989 Dec;7(12):1915–1925. doi: 10.1200/JCO.1989.7.12.1915. [DOI] [PubMed] [Google Scholar]
  23. Ohlsson K., Björk P., Bergenfeldt M., Hageman R., Thompson R. C. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990 Dec 6;348(6301):550–552. doi: 10.1038/348550a0. [DOI] [PubMed] [Google Scholar]
  24. Starnes H. F., Jr, Pearce M. K., Tewari A., Yim J. H., Zou J. C., Abrams J. S. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol. 1990 Dec 15;145(12):4185–4191. [PubMed] [Google Scholar]
  25. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  26. Urba W. J., Hartmann L. C., Longo D. L., Steis R. G., Smith J. W., 2nd, Kedar I., Creekmore S., Sznol M., Conlon K., Kopp W. C. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res. 1990 May 15;50(10):2979–2986. [PubMed] [Google Scholar]
  27. Virca G. D., Kim S. Y., Glaser K. B., Ulevitch R. J. Lipopolysaccharide induces hyporesponsiveness to its own action in RAW 264.7 cells. J Biol Chem. 1989 Dec 25;264(36):21951–21956. [PubMed] [Google Scholar]
  28. Wakabayashi G., Gelfand J. A., Jung W. K., Connolly R. J., Burke J. F., Dinarello C. A. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest. 1991 Jun;87(6):1925–1935. doi: 10.1172/JCI115218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ziegler-Heitbrock H. W., Appl B., Käfferlein E., Löffler T., Jahn-Henninger H., Gutensohn W., Nores J. R., McCullough K., Passlick B., Labeta M. O. The antibody MY4 recognizes CD14 on porcine monocytes and macrophages. Scand J Immunol. 1994 Nov;40(5):509–514. doi: 10.1111/j.1365-3083.1994.tb03497.x. [DOI] [PubMed] [Google Scholar]
  30. Ziegler-Heitbrock H. W. Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm. 1995;45(1):13–26. [PubMed] [Google Scholar]
  31. Ziegler-Heitbrock H. W., Passlick B., Käfferlein E., Coulie P. G., Izbicki J. R. Protection against lethal pneumococcal septicemia in pigs is associated with decreased levels of interleukin-6 in blood. Infect Immun. 1992 Apr;60(4):1692–1694. doi: 10.1128/iai.60.4.1692-1694.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES